Smiths Medical and Ivenix Partner to Revolutionize Infusion Management with First-Ever Comprehensive Suite of Infusion Solutions in US Healthcare Market
Summary
The long-term partnership, which includes a strategic investment from Smiths Medical, unites two innovators under a common goal of revolutionizing infusion management to improve patient safety and meet the needs of healthcare providers today and into the future. Today, infusion-related errors account for more than 50% of the 1.5 million adverse drug events reported annually to the FDA,1 and infusion-related adverse drug events cost the healthcare system more than $2 billion annually.2 Smiths Medical’s complementary portfolio of market-leading infusion systems CADD®-Solis and Medfusion® include syringe and ambulatory pumps that serve adult and neonatal critical care, operating rooms and pain management in both the hospital and home. “As a researcher focused on large volume IV smart pumps, I am well aware of the many safety and usability issues that exist with current products,” said Karen K. Giuliano, Ph.D., RN, FAAN, MBA, an Associate Professor and Co-director of the Nursing-Engineering Center for Innovation at the University of Massachusetts Amherst. The system received 510(k) clearance in 2019 and sets a new standard in infusion delivery by rethinking safety, simplicity and interoperability. The system is centered around both the patient and clinician and designed to reduce infusion-related errors and drive down the total cost of ownership.